Tailwinds' Take: continued execution by MTBC as they maintain guidance for outstanding growth. Very well run company that trades at a reasonable valuation and has the opportunity to continue being a consolidator in a fragmented industry. SOMERSET, N.J., May 14,...
LOS ANGELES – November 7, 2018 – HyreCar Inc. (Nasdaq: HYRE), the carsharing marketplace for ridesharing, today announced the Company has expanded access to its proprietary platform for drivers and vehicle owners in all 50 U.S. states. This expansion represents an...
JUPITER, FL / ACCESSWIRE / November 13, 2019 Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the...
Los Angeles, CA – June 6, 2019 – Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today announced a strategic partnership with digital therapeutics company Canary Health. "Catasys has built a unique, proprietary...
Tailwinds' Take: yet another positive study result for what will surely become a blockbuster supplement. CDXC stock has traded well off its highs. Great time to look at it.  The supplement nicotinamide riboside (NR) – a form of vitamin B3...
If you've been paying attention to me, you know that I've been very bullish on Imprimis Pharmaceuticals (IMMY). In particular, my thinking was that the stock was cheap and would perform very well going into the Eton IPO. This...
Tailwinds' Take: positive IP protection is going to position them well for inking a strategic investor in the next few months. ANN ARBOR, MI / February 15, 2018 / ENDRA Life Sciences Inc. ("ENDRA" or the "Company") (NASDAQ: NDRA), a developer of...
Introduction Merck’s (MRK) Keytruda, a PD-1 inhibitor, is quickly becoming the most broadly-used cancer treatment worldwide. EvaluatePharma projects revenue of over $12 billion by 2024, just behind Bristol-Myers Squibb’s (BMY) Opdivo and Roche Holdings’ (RHHBY) Tencentriq. Keytruda has shown amazing success...
SAN DIEGO, Aug. 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the second quarter 2018. Notable Highlights from the Second Quarter of 2018: Revenues of $10.4 million, up 51% year-over-year Gross ophthalmology-related revenue of $8.3 million, up 74% year-over-year Gross...
IRVINE, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today the financial results for the quarter ended September 30, 2017. Frank Jaksch, Jr., CEO and co-founder of ChromaDex commented, “The science continues to...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.